RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
Canada and Germany Advance Major LNG Supply Partnership 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
ECB’s Philip Lane Warns Middle East Conflict Could Keep Inflation Elevated 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
S&P 500 Hits Record High as Tech Rally Slows Amid Iran Peace Uncertainty 
Costco Q3 Fiscal 2026 Earnings Beat Expectations as Sales and E-Commerce Surge 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
UK Grocery Inflation Slows to 3.1% as Supermarket Price Pressures Ease in May 2026 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
Why the future of marijuana legalization remains hazy despite high public support 
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten 
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
